Roche Aktie [WKN: 851311 / ISIN: CH0012032113]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

28.06.24		CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (Roche Holding AG)
27.06.24		Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (Roche Holding AG)
27.06.24		Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (GlobeNewswire)
25.06.24		Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (GlobeNewswire)
25.06.24		Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (Roche Holding AG)
24.06.24		Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (GlobeNewswire)
24.06.24		Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (Roche Holding AG)
20.06.24		Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (Roche Holding AG)
20.06.24		Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (GlobeNewswire)
15.06.24		Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
15.06.24		Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
10.06.24		Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization (GlobeNewswire)
10.06.24		Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization (Roche Holding AG)
10.06.24		European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer (GlobeNewswire)
10.06.24		European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
07.06.24		Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (GlobeNewswire)
07.06.24		Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (Roche Holding AG)
29.05.24		FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
29.05.24		FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
27.05.24		Changes to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
27.05.24		Wechsel in der erweiterten Konzernleitung von Roche (GlobeNewswire)
27.05.24		Changes to the Roche Enlarged Corporate Executive Committee (GlobeNewswire)
22.05.24		Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk (Roche Holding AG)
22.05.24		Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk (GlobeNewswire)
21.05.24		FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
21.05.24		FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
16.05.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity (Roche Holding AG)
16.05.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity (GlobeNewswire)
15.05.24		Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer (GlobeNewswire)
15.05.24		Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer (Roche Holding AG)
24.04.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 (Roche Holding AG)
24.04.24		[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produ (GlobeNewswire)
24.04.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 (GlobeNewswire)
19.04.24		FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
19.04.24		FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer (GlobeNewswire)
17.04.24		Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS (GlobeNewswire)
17.04.24		Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS (Roche Holding AG)
15.04.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study (GlobeNewswire)
15.04.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study (Roche Holding AG)
11.04.24		Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis (Roche Holding AG)
11.04.24		Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis (GlobeNewswire)
26.03.24		Roche receives FDA approval for the first molecular test to screen for malaria in blood donors (Roche Holding AG)
26.03.24		Roche receives FDA approval for the first molecular test to screen for malaria in blood donors (GlobeNewswire)
12.03.24		Roche Annual General Meeting 2024 (GlobeNewswire)
12.03.24		Roche Generalversammlung 2024 (GlobeNewswire)
12.03.24		Roche Annual General Meeting 2024 (Roche Holding AG)
05.03.24		Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when add (GlobeNewswire)
25.02.24		New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies (GlobeNewswire)
25.02.24		New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies (Roche Holding AG)
16.02.24		FDA approves Xolair as first and only medicine for children and adults with one or more food allergies (Roche Holding AG)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Roche Peer Group Nachrichten

09:29		Freundlicher Handel: STOXX 50-Anleger greifen zum Start des Mittwochshandels zu
09:29		Börse London in Grün: FTSE 100 zum Start des Mittwochshandels im Plus
09:29		Zuversicht in Frankfurt: DAX verbucht zum Handelsstart Gewinne
09:29		Börse Frankfurt in Rot: LUS-DAX sackt zum Handelsstart ab
09:29		Freundlicher Handel: Euro STOXX 50 zum Start des Mittwochshandels mit positivem Vorzeichen
09:29		SIX-Handel: SPI zum Start des Mittwochshandels mit Gewinnen

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.02.2025 12:21
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie [WKN: 851311 / ISIN: CH0012032113]

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten